Aberrant b-catenin expression as determined by assessment of its subcellular localization constitutes a surrogate marker of Wnt signalling pathway activation and has been reported in a subset of breast cancers. The association of b-catenin/Wnt pathway activation with clinical outcome and the mechanisms leading to its activation in breast cancers still remain a matter of controversy. The aims of this study were to address the distribution of b-catenin expression in invasive breast cancers, the correlations between b-catenin expression and clinicopathological features and survival of breast cancer patients, and to determine whether aberrant b-catenin expression is driven by CTNNB1 (b-catenin encoding gene) activating mutations. Immunohistochemistry was performed on a tissue microarray containing 245 invasive breast carcinomas from uniformly treated patients, using two anti-b-catenin monoclonal antibodies. Selected samples were subjected to CTNNB1 exon 3 mutation analysis by direct gene sequencing. A good correlation between the two b-catenin antibodies was observed (Spearman's r 40.62, Po0.001). Respectively, 31 and 11% of the cases displayed lack/reduction of b-catenin membranous expression and nuclear accumulation. Complete lack of b-catenin expression was significantly associated with invasive lobular carcinoma histological type. Subgroup analysis of non-lobular cancers or non-lobular grade 3 carcinomas revealed that lack/reduction of b-catenin membranous expression and/or nuclear accumulation were significantly associated with oestrogen receptor negativity, absence of HER2 gene amplification and overexpression, lack/reduction of E-cadherin expression and tumours of triple-negative and basal-like phenotype. Univariate survival analysis revealed a significant association between b-catenin nuclear expression and shorter metastasis-free and overall survival in the whole cohort; however, b-catenin nuclear expression was not an independent predictor of outcome in multivariate analysis. No CTNNB1 mutations were identified in the 28 selected breast carcinomas analysed. In conclusion, b-catenin/Wnt pathway activation is preferentially found in triple-negative/basal-like breast carcinomas, is associated with poor clinical outcome and is unlikely to be driven by CTNNB1 mutations in breast cancer.
b-Catenin is a multifunctional protein located to the intracellular side of the cytoplasmic membrane coded by the CTNNB1 gene, which maps to chromosome 3p22.1. It has a critical role in cell-tocell adhesion by linking cadherins to the actin cytoskeleton and has a central role in transcriptional regulation in the Wnt signalling pathway. 1 Indeed, upon Wnt activation, b-catenin is translocated from the membrane to the cytoplasm and nucleus, where it interacts with transcriptional activators to modulate a number of target genes associated with increased growth, invasion and cellular transformation, such as c-MYC 2 or cyclin D1. 3, 4 There are numerous lines of evidence to implicate the importance of b-catenin deregulation and CTNNB1 activating mutations in carcinogenesis. 1, [3] [4] [5] [6] [7] [8] [9] Several studies have addressed the issue of b-catenin/Wnt pathway dysfunction in breast cancer. 3, [10] [11] [12] [13] [14] [15] [16] [17] Our previous study on spindle lesions of the breast demonstrated that aberrant b-catenin expression is often observed in metaplastic carcinomas of the breast, indicating that Wnt canonical pathway activation is found in at least a subset of breast cancers. 18 Expression of b-catenin in breast cancer and its association with outcome have been a matter of controversy. Although some have reported that aberrant b-catenin expression is found in breast cancers of poor outcome 3, 13, 15 and of the basal-like phenotype, 19 others have failed to demonstrate a correlation between b-catenin aberrant expression and outcome. 11, 14, 16, 17, 20 This is not surprising, given the difficulties in assessing b-catenin/Wnt pathway activation in breast cancer, because of the complexity of this molecular pathway, the challenging interpretation of b-catenin subcellular localization, specificity of different antibodies and other technical issues. 12, 20 The mechanisms underpinning b-catenin/Wnt pathway activation in breast cancer remain poorly understood. CTNNB1 activating mutations and APC inactivating mutations are some of the possible mechanisms leading to b-catenin nuclear accumulation. The prevalence of these molecular abnormalities is highly debated in breast cancer. [21] [22] [23] [24] Although some authors have described CTNNB1 mutations in up to 26% of metaplastic carcinomas of the breast, 25 we 18 and others 7 have failed to confirm the presence of CTNNB1 mutations in this histological type of breast tumours. Notwithstanding the fact that most recent studies agree in that b-catenin/ Wnt pathway is activated in at least a subset of breast cancers, 15, 18, 19 the molecular alterations underlying aberrant b-catenin expression are yet to be elucidated.
The aims of this study were threefold: (1) to address the distribution of b-catenin expression as defined by immunohistochemistry using two antibodies in a cohort of 245 invasive breast carcinomas uniformly treated with anthracycline-based chemotherapy, (2) to correlate b-catenin expression with clinicopathological characteristics and outcome of primary breast cancer patients and (3) to investigate whether activation of b-catenin/Wnt pathway in breast cancer is driven by CTNNB1 gene mutation.
Materials and methods

Case Selection and Tissue Microarray
A cohort of 245 patients with invasive breast cancer was included in a tissue microarray containing three replicate 0.6 mm cores. All patients were diagnosed and managed at the Royal Marsden Hospital, London, UK, between 1994 and 2000. All patients were primarily treated with surgery followed by anthracycline-based chemotherapy. Adjuvant endocrine therapy was prescribed for patients with oestrogen receptor-positive tumours (tamoxifen alone in 96% of the patients for the available follow-up period). Complete follow-up was available for 244 patients, ranging from 0.5 to 125 months (median ¼ 67 months, mean ¼ 67 months). Tumours were graded according to a modified Bloom-Richardson scoring system, 26 and size was categorized according to the TNM staging. 27 The study was approved by the Royal Marsden Hospital Ethics Committee.
Immunohistochemistry
Immunohistochemistry was performed on 3 mmthick tissue microarray sections. For b-catenin immunohistochemistry, two commercially available monoclonal antibodies raised against the C-terminal domain of b-catenin were used, clone 14/b-catenin (BD Transduction Laboratories, San Jose, CA, USA) and 17C2 (Novocastra/Leica, Newcastle Upon Tyne, UK), which were used in 1:6000 and 1:100 dilutions, respectively, as previously described 18 and summarized in Supplementary Table 1 . Immunohistochemical analysis with the 14/b-catenin clone was performed with the observers blinded to the results of the analysis of 17C2 clone. Results of b-catenin immunohistochemistry obtained with each antibody were analysed independently by two of the authors (ML-T and FCG) using the Allred scoring system for cytoplasmic and nuclear reactivity. This scoring system combines the staining intensity and the percentage of stained cells (intensity score 0-3 þ % score 0-5). 28 An Allred score of 42 was considered as positive. b-catenin membranous staining was scored according to a previously used system for E-cadherin. 29 Briefly, the proportion of stained cells with complete membranous staining was recorded in four categories: 0, 0-10%; 1, 10-o25%; 2, 25-o50%; 3, 50-75%; and 4, 475%. Expression of b-catenin was considered normal when scores were Z3, reduced when equal to 2, and negative when scores were o2.
b-Catenin expression was correlated with the expression of oestrogen receptor, progesterone receptor, HER2, epidermal growth factor receptor (EGFR), cytokeratin (CK) 14, CK5/6 and CK17, Ki-67, p53, topoisomerase II a (TOP2A), caveolin-1 (CAV1), caveolin-2 (CAV2), FOXA1, E-cadherin, CD44, Bcl2, nestin and cyclin D1, and with amplification of CCND1, HER2, TOP2A and MYC. Details of the methods and results of the above proteins are described elsewhere 30, 31 and summarized in Supplementary Table 1 . The prevalence of CCND1, HER2, TOP2A and MYC gene amplification was assessed by chromogenic in situ hybridization with SpotLight CISH probes (Invitrogen, Paisley, UK) and results not in relation to b-catenin expression were reported elsewhere. 32, 33 Based upon the expression of HER2, oestrogen receptor, CK5/6 and EGFR, b-Catenin pathway in breast cancer tumours were classified into basal, HER2 and luminal according to the immunohistochemical panel proposed by Nielsen et al.
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Microdissection and DNA Extraction
Cases with b-catenin nuclear expression and/or of triple-negative phenotype (ie, oestrogen receptor-, progesterone receptor-and HER2-negative) from the tissue microarray were selected for CTNNB1 sequencing analysis based on an Allred score for b-catenin nuclear staining ¼ 2 (n ¼ 9) or 42 (n ¼ 19). All cases were microdissected to ensure 475% of purity of neoplastic cells. Microdissection of formalin-fixed paraffin-embedded samples was performed with a sterile needle under a stereomicroscope (Olympus SZ61, Tokyo, Japan) from ten consecutive 8 mm thick sections stained with nuclear fast red as previously described. 35 DNA was extracted using the DNeasy Kit (Qiagen, Crawley, UK) according to the manufacturer's recommendations. DNA concentration was measured with the PicoGreen -assay as per the manufacturer's instructions (Invitrogen). 35 Out of the 30 carcinomas selected for the CTNNB1 mutation analysis, microdissection yielded sufficient DNA of optimal quality in 28 samples.
CTNNB1 Mutation Analysis
Sequencing of known mutation hotspots of CTNNB1 on exon 3 5, 9, 21, 23, 25 was performed in 19 invasive carcinomas of the breast displaying b-catenin nuclear expression, and 9 cases with a b-catenin nuclear Allred score of 2 (ie, considered as negative) and of triple-negative phenotype. As previously described, 18 positive controls (ie, DNA samples of the HCT116 colon cancer cell line 36 and of one formalinfixed paraffin-embedded breast fibromatosis, which harbored an exon 3 CTNNB1 mutation) were included in each experiment. The primers used for CTNNB1 sequencing were previously described. 25 A total of 50 ng tumour DNA was amplified and sequencing reactions were carried out using the DNA Sequencing Kit BigDye Terminator v 1.1 Cycle Sequencing Ready Reaction Mix (Applied Biosystems, Warrington, UK) as previously described. 36 Sequences of the forward and reverse strands were analysed with Mutation Surveyor software (Softgenetics, State College, PA, USA). All reactions were carried out in duplicate from the original DNA sample.
Statistical Analysis
Data analysis of b-catenin expression was performed with the results obtained with each antibody. The SPSS statistical software package was used for all statistical analysis. Spearman's correlations coefficient and unweighted k scores were assessed to determine the concordance between results obtained with the two anti-b-catenin antibodies used in this study. For each parameter, correlations between categorical variables were performed using the w 2 test and Fisher's exact test. Metastasis-free survival was expressed as the number of months from diagnosis to the occurrence of distant relapse. Disease-free survival was expressed as the number of months from diagnosis to the occurrence of distant, local relapse or death (disease-related death). Overall survival was expressed as the number of months from diagnosis to the occurrence of breast-cancer related death. Cumulative survival probabilities were calculated using the KaplanMeier method. Differences between survival rates were tested with the log-rank test. A P-value of r0.05 was considered as statistically significant.
Results
b-Catenin Expression in Invasive Breast Cancer
The results of the immunohistochemical analysis of b-catenin expression are summarized in Table 1 . Owing to lost/fragmented cores or cores without invasive tumour on tissue microarray sections, b-catenin expression data with both antibody clones were available in 221 out of 245 tumours. As previously described, 18 a good correlation between the two commercially available antibodies raised against b-catenin, clones 14/b-catenin and 17C2, was found. We observed statistically significant correlations between both antibodies for the semiquantitative assessment of b-catenin membranous (Spearman's r ¼ 0.863, Po0.0001), cytoplasmic (Spearman's r ¼ 0.620, Po0.0001), and nuclear expression (Spearman's r ¼ 0.676, Po0.0001) ( Table 1) . Analysis of agreement between the two antibodies revealed a substantial to nearly perfect agreement, with k scores of 0.801, 0.893 and 0.672 for membranous (negative vs reduced vs normal), cytoplasmic (positive vs negative) and nuclear (positive vs negative) reactivity, respectively.
In the 221 cases with available data for 14/bcatenin clone, b-catenin membranous expression was normal in 152 (69%) cases, reduced in 19 (9%) cases and negative in 50 (22%) cases. b-catenin cytoplasmic and nuclear expression (Allred score 42) was observed in 195 (88%) and 25 (11%) tumours, respectively (Table 1) . A weak cytoplasmic b-catenin expression was found in the neoplastic cells (ie, Allred score 42) in most of the tumours, rendering the objective interpretation of b-catenin expression in this subcellular compartment challenging. Therefore, although cytosolic accumulation of b-catenin is considered to be an aberrant form of b-catenin expression and, potentially, indicative of Wnt pathway activation, 19, 25 in this study, aberrant expression was defined as lack/reduction of b-catenin membrane expression and/or b-catenin nuclear expression (n ¼ 83, 37%). Of the total of (Table 2 and Figure 1 ). The majority of invasive ductal carcinomas, in particular those of low histological grade, displayed a normal pattern of b-catenin expression, that is, normal membranous expression (81%) without nuclear localization (88%; Figures 2a and b) ; whereas, in a way akin to E-cadherin expression in lobular carcinomas of the breast, 29 a strong correlation between lack of b-catenin membranous expression and lobular histological type was found (82%, Table 3 . Aberrant b-catenin expression (ie, lack/ reduction of membranous expression and/or nuclear expression) was significantly correlated with histo- b-Catenin pathway in breast cancer logical grade, presence of lympho-vascular invasion and lymph node metastasis, triple negativity (ie, oestrogen receptor-, progesterone receptor-and HER2-negative), basal-like phenotype and basal-like features, as described below (Po0.05, Table 3 ). As expected, given that the great majority of lobular carcinomas displayed complete lack of b-catenin expression, a significant correlation between E-cadherin and b-catenin membranous expression was found (Po0.001, Table 3 ). However, b-catenin nuclear expression was also associated with lack/ reduction of E-cadherin in the whole cohort (P ¼ 0.027, Table 3 ), indicating that the association between lack/reduction of both E-cadherin and aberrant b-catenin expression may be due not only to the lobular histology. Analysis of b-catenin expression with the clone 17C2 revealed similar associations (Table 4 ). Owing to the subjective nature of the analysis of b-catenin cytoplasmic expression, it is not surprising that no associations between b-catenin cytoplasmic expression and clinicopathological parameters were observed (Supplementary Table 2 ).
To avoid the confounding factor of the distinctive pattern of b-catenin expression in lobular carcinomas, b-catenin expression in the distinct subcellular compartments was investigated after the exclusion of all lobular carcinomas (n ¼ 186 cases). Associations similar to those observed in the analysis of b-catenin expression in the whole cohort were found (Tables 5  and 6, and Supplementary Table 2 ). Using 14/bcatenin clone, a significant inverse correlation between aberrant (reduced/negative membranous and/ or positive nuclear expression) b-catenin expression and oestrogen receptor, oestrogen receptor pathwayassociated parameters, such as progesterone receptor, FOXA1, cyclin D1 and Bcl2, and HER2 gene amplification and overexpression was found (Po0.05, Table 5 ). Furthermore, a positive correlation was observed between aberrant b-catenin expression and expression of EGFR, basal CKs (CK5/6, CK14, CK17) and other markers typically found in basal-like breast carcinomas, 34, [37] [38] [39] [40] such as p53 positivity, high proliferation indices as defined by MIB-1 expression, expression of CAV1, CAV2 and nestin (Po0.05, Table  5 ). Not surprisingly, aberrant b-catenin expression was significantly associated with triple-negative and basal-like phenotypes (Table 5 and Figures 3a, b and  4) . It is noteworthy that despite the exclusion of lobular carcinomas, the association between reduction/lack of E-cadherin expression and both lack/ reduction of b-catenin membranous staining and nuclear b-catenin accumulation was still significant (Table 5 ). Similar observations were obtained when tumours were analysed with the 17C2 clone (Table 6 and Figures 3c and d) .
As the vast majority of basal-like and triplenegative tumours are of histological grade 3, one Tables 7 and 8 ). Taken together, these results provide strong circumstantial evidence to suggest that Wnt pathway is preferentially activated in triple-negative/basal-like breast cancers. Given the association between aberrant b-catenin expression and clinicopathological features associated with poor outcome, it is not surprising that univariate survival analysis revealed that b-catenin nuclear expression as defined by 14/b-catenin clone was significantly associated with decreased metastasis-free survival (P ¼ 0.0216, Figure 5 ) and overall survival (P ¼ 0.0237, Figure 5 ). Furthermore, a trend for an association between b-catenin nuclear expression and decreased disease-free survival was observed (P ¼ 0.0873, Figure 5 ). We did not observe any significant correlation between b-catenin membranous or cytoplasmic expression and survival (data not shown). Multivariate survival analysis demonstrated that b-catenin nuclear expression was not associated with the outcome of breast cancer patients when other clinicopathological parameters were included in the model (ie, tumour size, lymph node b-Catenin pathway in breast cancer FC Geyer et al metastasis, oestrogen receptor, progesterone receptor and HER2 status, proliferation index as assessed by MIB-1 immunostaining, and basal-like markers; data not shown). No significant correlation between b-catenin expression and outcome could be observed when using 17C2 clone (data not shown).
Absence of CTNNB1 Mutation in Breast Carcinomas Displaying Aberrant b-Catenin Expression
Given that aberrant b-catenin nuclear expression was found in 11% of the breast cancers studied, we investigated the presence of CTNNB1 mutations in No exon 3 CTNNB1 gene mutations were found. Positive controls, included in each experiment, showed the expected presence of the previously reported CTNNB1 mutation on exon 3 (deletion of codon 45) in the HCT116 colorectal cancer cell line. 36 In addition, one formalin-fixed paraffinembedded sample of breast fibromatosis previously described 18 and displaying a CTNNB1 mutation on exon 3 (25195T4TC:45S4S/P) was also used as a positive control, confirming the accuracy of our sequencing technique. Taken together with our previous observations derived from the CTNNB1 sequencing of 21 metaplastic breast carcinomas, 18 these results suggest that b-catenin/Wnt pathway activation in breast cancer is not commonly driven by CTNNB1 mutations.
Discussion
In this study we report that b-catenin expression in a large series of invasive breast carcinomas is aberrant in invasive lobular carcinomas and in a subgroup of triple-negative and basal-like breast cancers, as defined by a validated immunohistochemical surrogate panel. 34 Our results expand on those of Khramtsov et al, 19 as we have not only confirmed the association between b-catenin nuclear expression in basal-like cancers, but also demonstrated its association with proliferation markers, p53, CAV1, CAV2 and nestin. 34, [37] [38] [39] We have also observed a statistically significant inverse correlation between b-catenin nuclear expression and lymph node metastasis at presentation, in the whole cohort (P ¼ 0.044) and in the non-lobular (P ¼ 0.017) and non-lobular grade 3 (P ¼ 0.009) subgroups. This should not come as a surprise, given the reported lower frequency of lymph node metastasis in triplenegative 30 and basal-like 41 cancers. Finally, our results further support our recent observations that metaplastic breast carcinomas, 7, 18 tumours that consistently display a basal-like phenotype, [42] [43] [44] often display b-catenin aberrant expression but lack CTNNB1 gene mutations.
The prevalence of b-catenin/Wnt pathway activation and its association with outcome in breast cancer are contentious issues. Several studies have failed to demonstrate any association between b-catenin aberrant expression and outcome of breast cancer patients. 11, 12, 14, 16, 20, 45 Our data derived from the analysis of a cohort of 245 breast cancer patients uniformly treated with anthracycline-based chemotherapy and those from recent studies 3, 13, 15, 19 provide strong circumstantial evidence that aberrant b-catenin expression is associated with a subset of patients of adverse outcome. It should be noted, however, that although b-catenin nuclear expression is significantly correlated with shorter metastasisfree and overall survival, it is not an independent predictor of outcome. Although current evidence supports the contention that the b-catenin/Wnt pathway is activated in a subgroup of breast cancers, the mechanisms leading to b-catenin nuclear accumulation in breast cancer remain elusive. In this study we investigated the hypothesis that b-catenin nuclear expression would be driven by CTNNB1 activating gene mutations as previously suggested by Hayes et al. 25 No CTNNB1 mutations on exon 3 in 28 invasive breast carcinomas displaying b-catenin nuclear expression and/or triple-negative phenotype were found. This observation, which is in agreement with our previous CTNNB1 mutation analysis in metaplastic breast carcinoma and studies from other groups, 7, 18 supports the hypothesis that b-catenin nuclear accumulation in breast cancer is not driven by mutations in CTNNB1 exon 3. Alternatively, b-catenin nuclear expression may stem from mutations affecting other exons of the CTNNB1 gene or other genes in the Wnt pathway (eg, the APC gene). It has been demonstrated that in colorectal cancers, copy number losses of APC gene may cooperate with inactivating APC mutations for complete APC protein loss of function and promote nuclear b-catenin translocation in tumour cells. 46, 47 Importantly, there is evidence to suggest that in breast cancer, APC mRNA expression levels are determined by APC gene copy numbers. 47 We, therefore, performed a hypothesis generating re-analysis of microarraybased comparative genomic hybridization and gene (Figures 6 and 7) . Taken together, our results warrant further studies to determine whether APC deletions, mutations and gene promoter methy- lation may be the driver of b-catenin/Wnt pathway activation in a subgroup of basal-like and triplenegative breast cancers. A significant correlation between b-catenin aberrant expression and reduction/lack of E-cadherin was found in the non-lobular and non-lobular grade 3 subgroups (Po0.05, Tables 5-8). We and others 29, 50 have previously shown that reduction of E-cadherin expression, one of the surrogate markers of epithelial-to-mesenchymal transition, 50 is associated with non-lobular breast carcinomas of basal-like and triple-negative phenotypes. 29 Hence, it is plausible Nuclear positive Figure 5 b-Catenin nuclear expression is associated with poor survival. Kaplan-Meier curves for disease-free survival (a), metastasis-free survival (b) and overall survival (c) for 221 patients uniformly treated with anthracycline-based chemotherapy. Invasive breast carcinomas with b-catenin nuclear expression as defined by the 14/b-catenin clone (dark grey) are significantly associated with shorter metastasis-free survival and overall survival (Po0.05). A similar but non-significant trend was also observed with disease-free survival. 2) loss, as defined by microarray-based comparative genomic hybridization performed with the 32K bacterial artificial chromosome tiling path array, 48 in a previously published cohort of 95 grade 3 invasive breast cancers 48, 49 according to the molecular subtypes of breast cancer as defined by the immunohistochemical surrogate described by Nielsen et al. 34 (b) Correlations between APC mRNA expression levels, as defined by the WG6 Illumina expression arrays (ArrayExpress http://www.ebi.ac.uk/microarray-as/ae/; accession number E-TABM-543) 49 and APC loss (as defined by microarray-based comparative genomic hybridization performed with the 32K bacterial artificial chromosome tiling path array 48 ) in basal-like breast cancers (n ¼ 13). and basal-like cancers obtained from re-analysis of the data from Natrajan et al. 48 Log 2 ratios are plotted on the x axis against each clone according to genomic location on the y axis. BACs categorized as displaying genomic gains or amplification are plotted in green and those categorized as genomic losses in red, as defined by previously validated cutoffs for circular binary segmentation-smoothed log 2 ratios.
b-Catenin pathway in breast cancer FC Geyer et al that the activation of the b-catenin/Wnt pathway in these tumours may be the consequence of a global epithelial-to-mesenchymal transition programme, which is characteristic of at least a subset of basal-like tumours, including metaplastic breast cancers. 50, 51 In conclusion, b-catenin loss of membrane expression is a characteristic feature of invasive lobular carcinomas. b-catenin/Wnt canonical pathway activation, as defined by nuclear expression, is found in a subgroup of invasive breast cancers of triple-negative and basal-like phenotypes and is unlikely to be driven by CTNNB1 activating gene mutations. Studies exploring alternative mechanisms of b-catenin/Wnt pathway activation are warranted.
